Drug Name Recognition Research Articles

Exploration of biomedical knowledge for recurrent glioblastoma using natural language processing deep learning models

BackgroundEfficient exploration of knowledge for the treatment of recurrent glioblastoma (GBM) is critical for both clinicians and researchers. However, due to the large number of clinical trials and published articles, searching for this knowledge is very labor-intensive. In the current study, using natural language processing (NLP), we analyzed medical research corpora related to recurrent glioblastoma to find potential targets and treatments.MethodsWe fine-tuned the ‘SAPBERT’, which was pretrained on biomedical ontologies, to perform question/answering (QA) and name entity recognition (NER) tasks for medical corpora. The model was fine-tuned with the SQUAD2 dataset and multiple NER datasets designed for QA task and NER task, respectively. Corpora were collected by searching the terms “recurrent glioblastoma” and “drug target”, published from 2000 to 2020 in the Web of science (N = 288 articles). Also, clinical trial corpora were collected from ‘clinicaltrial.gov’ using the searching term of ‘recurrent glioblastoma” (N = 587 studies).ResultsFor the QA task, the model showed an F1 score of 0.79. For the NER task, the model showed F1 scores of 0.90 and 0.76 for drug and gene name recognition, respectively. When asked what the molecular targets were promising for recurrent glioblastoma, the model answered that RTK inhibitors or LPA-1 antagonists were promising. From collected clinical trials, the model summarized them in the order of bevacizumab, temozolomide, lomustine, and nivolumab. Based on published articles, the model found the many drug-gene pairs with the NER task, and we presented them with a circus plot and related summarization (https://github.com/bigwiz83/NLP_rGBM).ConclusionUsing NLP deep learning models, we could explore potential targets and treatments based on medical research and clinical trial corpora. The knowledge found by the models may be used for treating recurrent glioblastoma.

Medicine Drug Name Detection Based Object Recognition Using Augmented Reality.

Augmented Reality (AR) is an innovation that empowers us in coordinating computerized data into the client's real-world space. It offers an advanced and progressive methodology for medicines, providing medication training. AR aids in surgery planning, and patient therapy discloses complex medical circumstances to patients and their family members. With accelerated upgrades in innovation, the ever-increasing number of medical records get accessible, which contain a lot of sensitive medical data, similar to medical substances and relations between them. To exploit the clinical texts in these data, it is important to separate significant data from these texts. Drugs, along with some kind of the fundamental clinical components, additionally should be perceived. Drug name recognition (DNR) tries to recognize drugs specified in unstructured clinical texts and order them into predefined classifications, which is utilized to deliver a connected 3D model inside the present reality client space. This work shows the utilization of AR to give an active and visual representation of data about medicines and their applications. The proposed method is a mobile application that uses a native camera and optical character recognition algorithm (OCR) to extract the text on the medicines. The extracted text is over and above processed using natural language processing (NLP) tools which are then used to identify the generic name and category of the drug using the dedicated DNR database. The database used for the system is scraped using various resources of medical studies and is named a medi-drug database from a development standpoint. 3D model prepared particularly for the drug is then presented in AR using ArCore. The results obtained are encouraging. The proposed method can detect the text with an average time of 0.005 s and can produce the visual representation of the output with an average time of 1.5 s.

A Novel Genetic Artificial Bee Inspired Neural Network Model for Drug Name Recognition

Drug names recognition (DNR) that seeks to discriminate drug mentions within the unstructured biomedical texts and categorize them into drug classes, is an essential task in mining medical information. The neural network structure considerably influences their overall performance. If there were lots of neurons within a network, it might fit the training dataset better, and the network might achieve few training errors, however it could be prone to over-fitting and the poor network generalization. Therefore, this paper proposes a novel network model for DNR based on a hybrid genetic artificial bee colony (GABC) algorithm. The algorithm enhances exploitation process of ABC and avoids the premature convergence problem by combining genetic operators into the ABC. These operators are hybridized in two phases of ABC: (1) exploitation process of onlooker bees phase, to enhance information sharing in between employed and onlooker bees which can find better solutions, and (2) scout bees phase to improve the replacement of any exhausted solution. The proposed network model for DNR was compared to some ether established models using different bio-inspired algorithms. The results reveal that the proposed model outperforms the other models in terms of predictive ability and computational time.

A Method for Identifying Local Drug Names in Xinjiang Based on BERT-BiLSTM-CRF

This paper proposes a BERT-BiLSTM-CRF Xinjiang local drug name recognition method embedded in the BERT (Bidirectional Encoder Representations from Transformers) pre-training language model. The method is pre-trained by the two-way Transformer structure. The training method of MaskLM is used to randomly select some Chinese characters of the input sequence to be replaced with special symbols. The word vector is dynamically generated according to the position information of Chinese characters in Xinjiang local drug names, and then the word vector sequence is input into two directions. The LSTM layer is trained to obtain the dependencies between the sequences. Finally, the CRF module takes the joint distribution probability of the entire marker sequence as the output, and obtains the global optimal test result. The model obtains the named entity recognition on the Xinjiang local drug corpus. The accuracy rate is 95.77%, the recall rate is 89.47%, and the F value is 92.52%. The experimental results show that BERT-BiLSTM-CRF can effectively improve the evaluation indexes of Xinjiang local drug name identification methods in practical applications.

Terminologies augmented recurrent neural network model for clinical named entity recognition.

We aimed to enhance the performance of a supervised model for clinical named-entity recognition (NER) using medical terminologies. In order to evaluate our system in French, we built a corpus for 5 types of clinical entities. We used a terminology-based system as baseline, built upon UMLS and SNOMED. Then, we evaluated a biGRU-CRF, and a hybrid system using the prediction of the terminology-based system as feature for the biGRU-CRF. In French, we built APcNER, a corpus of 147 documents annotated for 5 entities (Drug names, Signs or symptoms, Diseases or disorders, Diagnostic procedures or lab tests and Therapeutic procedures). We evaluated each NER systems using exact and partial match definition of F-measure for NER. The APcNER contains 4,837 entities, which took 28h to annotate. The inter-annotator agreement as measured by Cohen's Kappa was substantial for non-exact match (Κ=0.61) and moderate considering exact match (Κ=0.42). In English, we evaluated the NER systems on the i2b2-2009 Medication Challenge for Drug name recognition, which contained 8,573 entities for 268 documents, and i2b2-small a version reduced to match APcNER number of entities. For drug name recognition on both i2b2-2009 and APcNER, the biGRU-CRF performed better that the terminology-based system, with an exact-match F-measure of 91.1% versus 73% and 81.9% versus 75% respectively. For i2b2-small and APcNER, the hybrid system outperformed the biGRU-CRF, with an exact-match F-measure of 87.8% versus 85.6% and 86.4% versus 81.9% respectively. On APcNER corpus, the micro-average F-measure of the hybrid system on the 5 entities was 69.5% in exact match and 84.1% in non-exact match. APcNER is a French corpus for clinical-NER of five types of entities which covers a large variety of document types. The extension of the supervised model with terminology has allowed an easy increase in performance, especially for rare entities, and established near state of the art results on the i2b2-2009 corpus.

A two-stage deep learning approach for extracting entities and relationships from medical texts.

This work presents a two-stage deep learning system for Named Entity Recognition (NER) and Relation Extraction (RE) from medical texts. These tasks are a crucial step to many natural language understanding applications in the biomedical domain. Automatic medical coding of electronic medical records, automated summarizing of patient records, automatic cohort identification for clinical studies, text simplification of health documents for patients, early detection of adverse drug reactions or automatic identification of risk factors are only a few examples of the many possible opportunities that the text analysis can offer in the clinical domain. In this work, our efforts are primarily directed towards the improvement of the pharmacovigilance process by the automatic detection of drug-drug interactions (DDI) from texts. Moreover, we deal with the semantic analysis of texts containing health information for patients. Our two-stage approach is based on Deep Learning architectures. Concretely, NER is performed combining a bidirectional Long Short-Term Memory (Bi-LSTM) and a Conditional Random Field (CRF), while RE applies a Convolutional Neural Network (CNN). Since our approach uses very few language resources, only the pre-trained word embeddings, and does not exploit any domain resources (such as dictionaries or ontologies), this can be easily expandable to support other languages and clinical applications that require the exploitation of semantic information (concepts and relationships) from texts. During the last years, the task of DDI extraction has received great attention by the BioNLP community. However, the problem has been traditionally evaluated as two separate subtasks: drug name recognition and extraction of DDIs. To the best of our knowledge, this is the first work that provides an evaluation of the whole pipeline. Moreover, our system obtains state-of-the-art results on the eHealth-KD challenge, which was part of the Workshop on Semantic Analysis at SEPLN (TASS-2018).

PharmacoNER Tagger: a deep learning-based tool for automatically finding chemicals and drugs in Spanish medical texts.

Automatically detecting mentions of pharmaceutical drugs and chemical substances is key for the subsequent extraction of relations of chemicals with other biomedical entities such as genes, proteins, diseases, adverse reactions or symptoms. The identification of drug mentions is also a prior step for complex event types such as drug dosage recognition, duration of medical treatments or drug repurposing. Formally, this task is known as named entity recognition (NER), meaning automatically identifying mentions of predefined entities of interest in running text. In the domain of medical texts, for chemical entity recognition (CER), techniques based on hand-crafted rules and graph-based models can provide adequate performance. In the recent years, the field of natural language processing has mainly pivoted to deep learning and state-of-the-art results for most tasks involving natural language are usually obtained with artificial neural networks. Competitive resources for drug name recognition in English medical texts are already available and heavily used, while for other languages such as Spanish these tools, although clearly needed were missing. In this work, we adapt an existing neural NER system, NeuroNER, to the particular domain of Spanish clinical case texts, and extend the neural network to be able to take into account additional features apart from the plain text. NeuroNER can be considered a competitive baseline system for Spanish drug and CER promoted by the Spanish national plan for the advancement of language technologies (Plan TL).

LSTMVoter: chemical named entity recognition using a conglomerate of sequence labeling tools

BackgroundChemical and biomedical named entity recognition (NER) is an essential preprocessing task in natural language processing. The identification and extraction of named entities from scientific articles is also attracting increasing interest in many scientific disciplines. Locating chemical named entities in the literature is an essential step in chemical text mining pipelines for identifying chemical mentions, their properties, and relations as discussed in the literature. In this work, we describe an approach to the BioCreative V.5 challenge regarding the recognition and classification of chemical named entities. For this purpose, we transform the task of NER into a sequence labeling problem. We present a series of sequence labeling systems that we used, adapted and optimized in our experiments for solving this task. To this end, we experiment with hyperparameter optimization. Finally, we present LSTMVoter, a two-stage application of recurrent neural networks that integrates the optimized sequence labelers from our study into a single ensemble classifier.ResultsWe introduce LSTMVoter, a bidirectional long short-term memory (LSTM) tagger that utilizes a conditional random field layer in conjunction with attention-based feature modeling. Our approach explores information about features that is modeled by means of an attention mechanism. LSTMVoter outperforms each extractor integrated by it in a series of experiments. On the BioCreative IV chemical compound and drug name recognition (CHEMDNER) corpus, LSTMVoter achieves an F1-score of 90.04%; on the BioCreative V.5 chemical entity mention in patents corpus, it achieves an F1-score of 89.01%.Availability and implementationData and code are available at https://github.com/texttechnologylab/LSTMVoter.

An attention-based BiLSTM-CRF approach to document-level chemical named entity recognition.

In biomedical research, chemical is an important class of entities, and chemical named entity recognition (NER) is an important task in the field of biomedical information extraction. However, most popular chemical NER methods are based on traditional machine learning and their performances are heavily dependent on the feature engineering. Moreover, these methods are sentence-level ones which have the tagging inconsistency problem. In this paper, we propose a neural network approach, i.e. attention-based bidirectional Long Short-Term Memory with a conditional random field layer (Att-BiLSTM-CRF), to document-level chemical NER. The approach leverages document-level global information obtained by attention mechanism to enforce tagging consistency across multiple instances of the same token in a document. It achieves better performances with little feature engineering than other state-of-the-art methods on the BioCreative IV chemical compound and drug name recognition (CHEMDNER) corpus and the BioCreative V chemical-disease relation (CDR) task corpus (the F-scores of 91.14 and 92.57%, respectively). Data and code are available at https://github.com/lingluodlut/Att-ChemdNER. yangzh@dlut.edu.cn or wangleibihami@gmail.com. Supplementary data are available at Bioinformatics online.

Recurrent neural networks with specialized word embeddings for health-domain named-entity recognition

BackgroundPrevious state-of-the-art systems on Drug Name Recognition (DNR) and Clinical Concept Extraction (CCE) have focused on a combination of text “feature engineering” and conventional machine learning algorithms such as conditional random fields and support vector machines. However, developing good features is inherently heavily time-consuming. Conversely, more modern machine learning approaches such as recurrent neural networks (RNNs) have proved capable of automatically learning effective features from either random assignments or automated word “embeddings”. Objectives(i) To create a highly accurate DNR and CCE system that avoids conventional, time-consuming feature engineering. (ii) To create richer, more specialized word embeddings by using health domain datasets such as MIMIC-III. (iii) To evaluate our systems over three contemporary datasets. MethodsTwo deep learning methods, namely the Bidirectional LSTM and the Bidirectional LSTM-CRF, are evaluated. A CRF model is set as the baseline to compare the deep learning systems to a traditional machine learning approach. The same features are used for all the models. ResultsWe have obtained the best results with the Bidirectional LSTM-CRF model, which has outperformed all previously proposed systems. The specialized embeddings have helped to cover unusual words in DrugBank and MedLine, but not in the i2b2/VA dataset. ConclusionsWe present a state-of-the-art system for DNR and CCE. Automated word embeddings has allowed us to avoid costly feature engineering and achieve higher accuracy. Nevertheless, the embeddings need to be retrained over datasets that are adequate for the domain, in order to adequately cover the domain-specific vocabulary.

LSTM-CRF for Drug-Named Entity Recognition

Drug-Named Entity Recognition (DNER) for biomedical literature is a fundamental facilitator of Information Extraction. For this reason, the DDIExtraction2011 (DDI2011) and DDIExtraction2013 (DDI2013) challenge introduced one task aiming at recognition of drug names. State-of-the-art DNER approaches heavily rely on hand-engineered features and domain-specific knowledge which are difficult to collect and define. Therefore, we offer an automatic exploring words and characters level features approach: a recurrent neural network using bidirectional long short-term memory (LSTM) with Conditional Random Fields decoding (LSTM-CRF). Two kinds of word representations are used in this work: word embedding, which is trained from a large amount of text, and character-based representation, which can capture orthographic feature of words. Experimental results on the DDI2011 and DDI2013 dataset show the effect of the proposed LSTM-CRF method. Our method outperforms the best system in the DDI2013 challenge.

A Novel Approach towards Medical Entity Recognition in Chinese Clinical Text.

Medical entity recognition, a basic task in the language processing of clinical data, has been extensively studied in analyzing admission notes in alphabetic languages such as English. However, much less work has been done on nonstructural texts that are written in Chinese, or in the setting of differentiation of Chinese drug names between traditional Chinese medicine and Western medicine. Here, we propose a novel cascade-type Chinese medication entity recognition approach that aims at integrating the sentence category classifier from a support vector machine and the conditional random field-based medication entity recognition. We hypothesized that this approach could avoid the side effects of abundant negative samples and improve the performance of the named entity recognition from admission notes written in Chinese. Therefore, we applied this approach to a test set of 324 Chinese-written admission notes with manual annotation by medical experts. Our data demonstrated that this approach had a score of 94.2% in precision, 92.8% in recall, and 93.5% in F-measure for the recognition of traditional Chinese medicine drug names and 91.2% in precision, 92.6% in recall, and 91.7% F-measure for the recognition of Western medicine drug names. The differences in F-measure were significant compared with those in the baseline systems.

A New Data Representation Based on Training Data Characteristics to Extract Drug Name Entity in Medical Text.

One essential task in information extraction from the medical corpus is drug name recognition. Compared with text sources come from other domains, the medical text mining poses more challenges, for example, more unstructured text, the fast growing of new terms addition, a wide range of name variation for the same drug, the lack of labeled dataset sources and external knowledge, and the multiple token representations for a single drug name. Although many approaches have been proposed to overwhelm the task, some problems remained with poor F-score performance (less than 0.75). This paper presents a new treatment in data representation techniques to overcome some of those challenges. We propose three data representation techniques based on the characteristics of word distribution and word similarities as a result of word embedding training. The first technique is evaluated with the standard NN model, that is, MLP. The second technique involves two deep network classifiers, that is, DBN and SAE. The third technique represents the sentence as a sequence that is evaluated with a recurrent NN model, that is, LSTM. In extracting the drug name entities, the third technique gives the best F-score performance compared to the state of the art, with its average F-score being 0.8645.

Effects of Semantic Features on Machine Learning-Based Drug Name Recognition Systems: Word Embeddings vs. Manually Constructed Dictionaries

Semantic features are very important for machine learning-based drug name recognition (DNR) systems. The semantic features used in most DNR systems are based on drug dictionaries manually constructed by experts. Building large-scale drug dictionaries is a time-consuming task and adding new drugs to existing drug dictionaries immediately after they are developed is also a challenge. In recent years, word embeddings that contain rich latent semantic information of words have been widely used to improve the performance of various natural language processing tasks. However, they have not been used in DNR systems. Compared to the semantic features based on drug dictionaries, the advantage of word embeddings lies in that learning them is unsupervised. In this paper, we investigate the effect of semantic features based on word embeddings on DNR and compare them with semantic features based on three drug dictionaries. We propose a conditional random fields (CRF)-based system for DNR. The skip-gram model, an unsupervised algorithm, is used to induce word embeddings on about 17.3 GigaByte (GB) unlabeled biomedical texts collected from MEDLINE (National Library of Medicine, Bethesda, MD, USA). The system is evaluated on the drug-drug interaction extraction (DDIExtraction) 2013 corpus. Experimental results show that word embeddings significantly improve the performance of the DNR system and they are competitive with semantic features based on drug dictionaries. F-score is improved by 2.92 percentage points when word embeddings are added into the baseline system. It is comparative with the improvements from semantic features based on drug dictionaries. Furthermore, word embeddings are complementary to the semantic features based on drug dictionaries. When both word embeddings and semantic features based on drug dictionaries are added, the system achieves the best performance with an F-score of 78.37%, which outperforms the best system of the DDIExtraction 2013 challenge by 6.87 percentage points.

Drug Name Recognition: Approaches and Resources

Drug name recognition (DNR), which seeks to recognize drug mentions in unstructured medical texts and classify them into pre-defined categories, is a fundamental task of medical information extraction, and is a key component of many medical relation extraction systems and applications. A large number of efforts have been devoted to DNR, and great progress has been made in DNR in the last several decades. We present here a comprehensive review of studies on DNR from various aspects such as the challenges of DNR, the existing approaches and resources for DNR, and possible directions.

Text mining for pharmacovigilance: Using machine learning for drug name recognition and drug–drug interaction extraction and classification

Pharmacovigilance (PV) is defined by the World Health Organization as the science and activities related to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem. An essential aspect in PV is to acquire knowledge about Drug–Drug Interactions (DDIs). The shared tasks on DDI-Extraction organized in 2011 and 2013 have pointed out the importance of this issue and provided benchmarks for: Drug Name Recognition, DDI extraction and DDI classification. In this paper, we present our text mining systems for these tasks and evaluate their results on the DDI-Extraction benchmarks. Our systems rely on machine learning techniques using both feature-based and kernel-based methods. The obtained results for drug name recognition are encouraging. For DDI-Extraction, our hybrid system combining a feature-based method and a kernel-based method was ranked second in the DDI-Extraction-2011 challenge, and our two-step system for DDI detection and classification was ranked first in the DDI-Extraction-2013 task at SemEval. We discuss our methods and results and give pointers to future work.

Enhancing of chemical compound and drug name recognition using representative tag scheme and fine-grained tokenization.

BackgroundThe functions of chemical compounds and drugs that affect biological processes and their particular effect on the onset and treatment of diseases have attracted increasing interest with the advancement of research in the life sciences. To extract knowledge from the extensive literatures on such compounds and drugs, the organizers of BioCreative IV administered the CHEMical Compound and Drug Named Entity Recognition (CHEMDNER) task to establish a standard dataset for evaluating state-of-the-art chemical entity recognition methods.MethodsThis study introduces the approach of our CHEMDNER system. Instead of emphasizing the development of novel feature sets for machine learning, this study investigates the effect of various tag schemes on the recognition of the names of chemicals and drugs by using conditional random fields. Experiments were conducted using combinations of different tokenization strategies and tag schemes to investigate the effects of tag set selection and tokenization method on the CHEMDNER task.ResultsThis study presents the performance of CHEMDNER of three more representative tag schemes-IOBE, IOBES, and IOB12E-when applied to a widely utilized IOB tag set and combined with the coarse-/fine-grained tokenization methods. The experimental results thus reveal that the fine-grained tokenization strategy performance best in terms of precision, recall and F-scores when the IOBES tag set was utilized. The IOBES model with fine-grained tokenization yielded the best-F-scores in the six chemical entity categories other than the "Multiple" entity category. Nonetheless, no significant improvement was observed when a more representative tag schemes was used with the coarse or fine-grained tokenization rules. The best F-scores that were achieved using the developed system on the test dataset of the CHEMDNER task were 0.833 and 0.815 for the chemical documents indexing and the chemical entity mention recognition tasks, respectively.ConclusionsThe results herein highlight the importance of tag set selection and the use of different tokenization strategies. Fine-grained tokenization combined with the tag set IOBES most effectively recognizes chemical and drug names. To the best of the authors' knowledge, this investigation is the first comprehensive investigation use of various tag set schemes combined with different tokenization strategies for the recognition of chemical entities.

CHEMDNER system with mixed conditional random fields and multi-scale word clustering.

BackgroundThe chemical compound and drug name recognition plays an important role in chemical text mining, and it is the basis for automatic relation extraction and event identification in chemical information processing. So a high-performance named entity recognition system for chemical compound and drug names is necessary.MethodsWe developed a CHEMDNER system based on mixed conditional random fields (CRF) with word clustering for chemical compound and drug name recognition. For the word clustering, we used Brown's hierarchical algorithm and Skip-gram model based on deep learning with massive PubMed articles including titles and abstracts.ResultsThis system achieved the highest F-score of 88.20% for the CDI task and the second highest F-score of 87.11% for the CEM task in BioCreative IV. The performance was further improved by multi-scale clustering based on deep learning, achieving the F-score of 88.71% for CDI and 88.06% for CEM.ConclusionsThe mixed CRF model represents both the internal complexity and external contexts of the entities, and the model is integrated with word clustering to capture domain knowledge with PubMed articles including titles and abstracts. The domain knowledge helps to ensure the performance of the entity recognition, even without fine-grained linguistic features and manually designed rules.

CHEMDNER: The drugs and chemical names extraction challenge.

Natural language processing (NLP) and text mining technologies for the chemical domain (ChemNLP or chemical text mining) are key to improve the access and integration of information from unstructured data such as patents or the scientific literature. Therefore, the BioCreative organizers posed the CHEMDNER (chemical compound and drug name recognition) community challenge, which promoted the development of novel, competitive and accessible chemical text mining systems. This task allowed a comparative assessment of the performance of various methodologies using a carefully prepared collection of manually labeled text prepared by specially trained chemists as Gold Standard data. We evaluated two important aspects: one covered the indexing of documents with chemicals (chemical document indexing - CDI task), and the other was concerned with finding the exact mentions of chemicals in text (chemical entity mention recognition - CEM task). 27 teams (23 academic and 4 commercial, a total of 87 researchers) returned results for the CHEMDNER tasks: 26 teams for CEM and 23 for the CDI task. Top scoring teams obtained an F-score of 87.39% for the CEM task and 88.20% for the CDI task, a very promising result when compared to the agreement between human annotators (91%). The strategies used to detect chemicals included machine learning methods (e.g. conditional random fields) using a variety of features, chemistry and drug lexica, and domain-specific rules. We expect that the tools and resources resulting from this effort will have an impact in future developments of chemical text mining applications and will form the basis to find related chemical information for the detected entities, such as toxicological or pharmacogenomic properties.

A document processing pipeline for annotating chemical entities in scientific documents.

BackgroundThe recognition of drugs and chemical entities in text is a very important task within the field of biomedical information extraction, given the rapid growth in the amount of published texts (scientific papers, patents, patient records) and the relevance of these and other related concepts. If done effectively, this could allow exploiting such textual resources to automatically extract or infer relevant information, such as drug profiles, relations and similarities between drugs, or associations between drugs and potential drug targets. The objective of this work was to develop and validate a document processing and information extraction pipeline for the identification of chemical entity mentions in text.ResultsWe used the BioCreative IV CHEMDNER task data to train and evaluate a machine-learning based entity recognition system. Using a combination of two conditional random field models, a selected set of features, and a post-processing stage, we achieved F-measure results of 87.48% in the chemical entity mention recognition task and 87.75% in the chemical document indexing task.ConclusionsWe present a machine learning-based solution for automatic recognition of chemical and drug names in scientific documents. The proposed approach applies a rich feature set, including linguistic, orthographic, morphological, dictionary matching and local context features. Post-processing modules are also integrated, performing parentheses correction, abbreviation resolution and filtering erroneous mentions using an exclusion list derived from the training data. The developed methods were implemented as a document annotation tool and web service, freely available at http://bioinformatics.ua.pt/becas-chemicals/.